Beyondspring Pharmaceuticals Inc., of New York, reported mechanism-based analysis from phase II data showing that lead compound plinabulin, combined with docetaxel, in patients with advanced non-small-cell lung cancer (NSCLC), who have lung lesions greater than 3 cm, potentially could offer substantial improvement in overall survival.